SCHEMBL20134805

SCHEMBL20134805

Cc1cnc(NC2CCNC2)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 7/20 0.50
ATAD2 Q6PL18 6/20 0.50
PRKCI P41743 3/20 0.44
TAF1 P21675 1/20 0.43
BRD2 P25440 1/20 0.43
BRD3 Q15059 1/20 0.43
BRDT Q58F21 1/20 0.43
CHEK1 O14757 1/20 0.42
CHEK2 O96017 1/20 0.41
HRH4 Q9H3N8 2/20 0.41
HRH3 Q9Y5N1 2/20 0.41
HRH2 P25021 1/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
KMT2A Q03164 1/20 0.41
SYK P43405 2/20 0.41
KCNH2 Q12809 2/20 0.41
MAPK3 P27361 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135621 1.00 BRD4 (0.50) BRD4ATAD2PRKCITAF1BRD2
SCHEMBL20134803 1.00 BRD4 (0.50) BRD4ATAD2PRKCITAF1BRD2
Hydrochloric Acid SCHEMBL29688363 0.98 BRD4 (0.49) BRD4ATAD2PRKCITAF1BRD2
SCHEMBL20135638 0.91 BRD4 (0.50) BRD4ATAD2TAF1BRD2BRD3
Hydrochloric Acid SCHEMBL30996510 0.80 BRD4 (0.46) BRD4ATAD2PRKCICHEK1IRAK4
SCHEMBL27101676 0.76 BRD4 (0.46) BRD4ATAD2TAF1BRD2BRD3
SCHEMBL3973338 0.76 BRD4 (0.44) BRD4ATAD2PRKCICHEK2HRH4
SCHEMBL20134889 0.75 CHEK1 (0.33) BRD4ATAD2TAF1BRD2BRD3
SCHEMBL20135063 0.75 CHEK1 (0.33) BRD4ATAD2TAF1BRD2BRD3
SCHEMBL15830444 0.74 SYK (0.42) BRD4ATAD2TAF1BRD2BRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 BRD4 982/4885ATAD2 2311/4885PRKCI 3141/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 BRD4 1494/4885ATAD2 2574/4885PRKCI 2836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.